Clovis Oncology (NASDAQ:CLVSQ – Get Rating) and Oncotelic Therapeutics (OTCMKTS:OTLC – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Profitability
This table compares Clovis Oncology and Oncotelic Therapeutics' net margins, return on equity and return on assets.
Get Clovis Oncology alerts:| Net Margins | Return on Equity | Return on Assets | |
| Clovis Oncology | -189.37% | N/A | -57.78% |
| Oncotelic Therapeutics | N/A | -53.27% | -26.26% |
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Clovis Oncology and Oncotelic Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Clovis Oncology | 0 | 0 | 0 | 0 | N/A |
| Oncotelic Therapeutics | 0 | 0 | 0 | 0 | N/A |
Earnings & Valuation
This table compares Clovis Oncology and Oncotelic Therapeutics' revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Clovis Oncology | $148.76 million | 0.02 | -$264.52 million | ($1.83) | -0.01 |
| Oncotelic Therapeutics | $1.74 million | 9.01 | -$9.39 million | $0.03 | 1.33 |
Oncotelic Therapeutics has lower revenue, but higher earnings than Clovis Oncology. Clovis Oncology is trading at a lower price-to-earnings ratio than Oncotelic Therapeutics, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
24.5% of Clovis Oncology shares are held by institutional investors. 4.4% of Clovis Oncology shares are held by company insiders. Comparatively, 39.2% of Oncotelic Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Volatility & Risk
Clovis Oncology has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Oncotelic Therapeutics has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.
Summary
Oncotelic Therapeutics beats Clovis Oncology on 7 of the 11 factors compared between the two stocks.
About Clovis Oncology
(Get Rating)
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
About Oncotelic Therapeutics
(Get Rating)
Oncotelic Therapeutics, Inc. is a biopharmaceutical company. It engages in developing anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases. The company is currently developing OT-101 for various cancers and COVID-19, Artemisinin for COVID-19 and AI technologies for clinical development and manufacturing. Oncotelic Therapeutics was founded in 1988 and is headquartered in Agoura Hills, CA.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
